Syntheses, DNA binding and anticancer profiles of L-glutamic acid ligand and its copper(II) and ruthenium(III) complexes

Medicinal Chemistry

Volumn 9, Issue 1, 2013, Pages 11-21

  Ali, Imran ^a   Wani, Waseem A ^a   Saleem, Kishwar ^a   Wesselinova, Diana ^b  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

Author keywords

Copper and ruthenium complexes; DNA binding studies; Hemolytic assays; L Glutamic acid derivative; Molar conductance measurements; Solution stability and anticancer cell line activities

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; COPPER COMPLEX; ETHYLENEDIAMINE; FORMALDEHYDE; GLUTAMIC ACID; RUTHENIUM COMPLEX; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMATOGRAPHY; CONDUCTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG PURIFICATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SPECTROSCOPY;

EID: 84873300341     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340613804488297     Document Type: Article

References (56)

1. Nelson, L.D.; Cox, M.M. Lehninger Principles of Biochemistry, 4th ed.; W. H. Freeman: New York, 2005.
2. Medina, M.A. Glutamine and Cancer. J. Nutr., 2001, 131, 2539S- 2542S.
3. Conn, E.E.; Stumpf, P. K.; Bruening, G.; Doi, R. H. Outlines of Biochemistry, 5th ed.; John Wiley & Sons: New York, 2006.
4. Klimberg, M.D.V.S.; McClellan, J.L. Glutamine, Cancer, and its therapy. Am. J. Surg., 1996, 172, 418-424.
5. Souba, W.W. Glutamine and Cancer. Ann. Surg., 1993, 218, 715-716.
6. Bhattacharya, P.; Maity, P. Localization of phosphate dependent glutaminase in ascites fluid of ovarian cancer patient. Pathol. Oncol. Res., 2000, 6, 217-223.
7. Turner, A.; Mc Givan, J. Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem. J., 2003, 370, 403-410.
8. Bode, B.P.; Fuchas B.C.; Hurley, B.; Conroy, J.L.; Suetterlin, J.E.; Tanabe, K.K. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 28, G1062-G1067.
9. Kallinowski, L.; Runkel, S.; Fortmeyer, H.P.; Forster, H.; Vaupel, P. L-glutamine: a major substrate for tumor cells in vivo. Cancer Res. Clin. Oncol., 1987, 113, 209-215.
10. Collins, C.L.; Wasa, M.; Souba, W.W.; Abcouwer, S.F. Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines. J. Cell Physiol., 1998, 176, 166-178.
11. Ramos Lima, M.M.; de Mello, M.A.; Curi, R.; Walker, R. Walker 256 tumor growth causes marked changes of glutamine metabolism in rat small intestine. Cell Biochem. Funct., 2002, 20, 107-111.
12. Costa, C.; Huneau, J.F.; Tome, D. Characteristics of L-glutamine transport during Caco-2 cell differentiation. Biochem. Biophys. Acta, 2000, 1509, 95-102.
13. Aledo, J.C.; de Pedro, E.; Gomez-Fabre, P.M.; Nunez de Castro, I.N.; Marquez, J. Changes in mRNAs for enzymes of glutamine metabolism in the tumor-bearing mouse. Anticancer Res., 2000, 20, 1463-1467.
14. Bhattacharya, P.; Sett, S.; Maity, P. Effect of purified glutaminase from human ascites fluid on experimental tumour bearing mice. J. Exp. Clin. Cancer Res., 2001, 20, 599-607.
15. Matsuno, T.; Goto, I. Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res., 1992, 52, 1192-1196.
16. Chen, M.K.; Salloum, R.M.; Austgen, T.R.; Bland, J.B.; Bland, K.I; Copeland, E.M.; Souba, W.W. Tumor regulation of hepatic glutamine metabolism. J. Parenter. Enteral. Nutr., 1991, 15, 159-163.
17. Kumar, S.; Witzig, T.E.; Rajkumar, S.V. Thalidomide as an anticancer agent. J. Cell Mol. Med. 2002, 6, 160-174.
18. a) Prajda, N. Enzyme targets of antiglutamine agents in cancer chemotherapy. Adv. Enzyme Regul., 1985, 24, 207-223.
19. (b) Nagy, K.; Toth, S.; Palfia, Z.; Rez, G. Angiogenesis is continuous with two peaks during azaserine-induced rat pancreatic adenocarcinoma progression: an electron microscopic morphometrical study. Oncol. Rep., 2003, 10, 1999-2004.
20. Samanta, S.; Srikanth, K.; Banerjee, Y.S.; Debnath, B.; Gayen, S.; Jha, T. 5-N-Substituted-2-(substituted benzenesulphonyl) glutamines as antitumor agents. Part II: Synthesis, biological activity and QSAR study. Bioorg. Med. Chem., 2004, 12, 1413-1423.
21. Souba, W.W. Glutamine and Cancer. Ann. Surg., 1993, 218, 715-728.
22. Xiao, Y.; Caifeng, B.I.; Fan, Y.; Cui, C.; Xia, Z.; Ping, D.Q. Lglutamine Schiff base copper complex as a proteasome inhibitor and an apoptosis inducer in human cancer cells. Int. J. Oncol., 2008, 33, 1073-1079.
23. Liu, C.L.; Zhou, Y.J.; Li, Q.X.; Wang, L.J.; Liao, Z.R.; Xu, H.B. DNA damage by copper (II) complexes: Coordination-structural dependence of reactivities. J. Inorg. Biochem., 1999, 75, 233-240.
24. Bergamo, A.; Sava, G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans., 2011, 40, 7817-7823.
25. Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem., 2006, 13, 1085-107.
26. Brabec, V.; Novakova, O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist. Update, 2006, 9, 111-22.
27. Giovagnini, L.; Sitran, S.; Castagliuolo, I.; Brun, P.; Corsini, M.; Zanello, P.; Zoleo, A., Maniero, A.; Biondi, B.; Fregona, D. Ru(III)-based compounds with sulfur donor ligands: synthesis, characterization, electrochemical behaviour and anticancer activity. Dalton Trans., 2008, 47, 6699-6708.
28. Tan, S.J.; Yan, Y.K.; Lee, P.P.; Lim, K.H. Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Med. Chem., 2010, 2, 1591-1608.
29. Jansson, P.J.; Sharpe, P.C.; Bernhardt, P.V.; Richardson, D.R. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J. Med. Chem., 2010, 53, 5759-5769.
30. Reichmann, M.F.; Rice, S.A.; Thomas, C.A.; Doty, P. A further examination of the molecular weight and size of desoxypentose nucleic acid. J. Am. Chem. Soc., 1954, 76, 3047-3053.
31. Nasser, M.H.; El-Dossoki, F.I. Schiff Base Complexes Derived from 2-Acetylpyridine, Leucine, and Some Metal Chlorides: Their Preparation, Characterization, and Physical Properties. J. Chem. Eng. Data, 2008, 53, 2567-2572.
32. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65, 55-63.
33. Feigl, R. Spot Test in Organic Analyses, Elsevier: Amsterdam, 1966.
34. Nogrady, T. Medicinal Chemistry, a Biochemical Approach, Oxford University press: New York, 1985.
35. Krishna, C.H.; Mahapatra, C.M.; Dash, A.K. 4-, 5- and 6-coordinate complexes of copper(II) with substituted imidazoles. J. Inorg. Nucl. Chem., 1977, 39, 1253-1258.
36. Arjmand, F.; Aziz, M.; Chauhan, M. Synthesis, spectroscopic studies of new water-soluble Co(II) and Cu(II) macrocyclic complexes of 4,15-bis(2-hydroxyethyl)-2,4,6,13,15,17-hexaazatricyclodocosane: their interaction studies with calf thymus DNA and guanosine 50 monophosphate. J. Incl. Phenom. Macrocycl. Chem., 2008, 61, 265-278.
37. Stephenson, T.A.; Wilkinson, G. Acetato complexes of palladium(II). J. Inorg. Nucl. Chem., 1967, 29, 2122-2123.
38. Stephenson, T.A.; Morehouse, S.M.; Powell, A.R.; Heffer, J.P.; Wilkinson, G. Carboxylates of palladium, platinum, and rhodium, and their adducts. J. Chem. Soc., 1965, 3632-3640.
39. Nakamoto, K. Infrared Spectra of Inorganic and Co-ordination Compounds, 2nd ed.; John Wiley & Sons: New York, 1970.
40. Chaudhary, A.; Singh, R.V. Synthetic, spectroscopic and toxicological aspects of novel eighteen to twenty two membered tetraaza macrocycles and their bivalent manganese complexes. Ind. J. Chem., 2004, 43, 2529-2535.
41. Kemp W. Organic spectroscopy, Macmillan Press Ltd.; London, 1975.
42. Xu Z.D.; Liu, H.; Xiao, S.L.; Yang, M.; Bu, X.H. Synthesis, crystal structure, antitumor activity and DNA-binding study on the Mn(II) complex of 2H-5-hydroxy-1,2,5-oxadiazo[3,4-f]1,10-phenanthroline. J. Inorg. Biochem., 2002, 90, 79-84.
43. Wang, Y.; Yan, Z.Y. Synthesis, characterization and DNA-binding properties of three 3d-transition metal complexes of the Schiff base derived from diethenetriamine with PMBP. Tran. Metal Chem., 2005, 30, 902-906.
44. Marmur, J. Procedure for isolation of deoxyribonucleic acid from microorganism. J. Mol. Biol., 1961, 3, 208-214.
45. Stephanos, J.J.; Farina, S.A.; Addison, A.W. Iron ligand recognition by monomeric hemoglobins. Biochim. Biophy. Acta, 1996, 1295, 209-221.
46. Andrushchenko, V.V.; Leonenko, Z.; van de Sande, H.; Wieser, H. Vibrational CD (VCD) and atomic force microscopy (AMF) study of DNA interactions with Cr3+: VCD and AFM evidence of DNA condensation. Biopolymers, 2002, 61, 243-260.
47. Chen, J.; Wang, X.; Shao, Y.; Zhu, J.; Li, Y.; Xu, Q.; Guo, Z. A trinuclear copper(II) complex of 2,4,6-Tris(di-2-pyridylamine)-1,3,5-triazine shows prominent DNA cleavage activity. Inorg. Chem., 2007, 46, 3306-3312.
48. Chauhan, M.; Banerjee, K.; Arjmand, F. DNA binding studies of novel copper (II) containing L-tryptophan as chiral auxillary: in vitro antitumor activity of Cu-Sn2 complex in human neuroblastoma cells. Inorg. Chem., 2007, 46, 3072-3082.
49. Baldini, M.; Ferrari, M.B.; Bisceglie, F.; Pelosi, G.; Pinelli, S.; Tarasconi, P. Cu(II) complexes with heterocyclic substituted thiosemicarbazones: the case of 5-formyluracil. Synthesis, characterization, X-ray structures, DNA interaction studies, and biological activity. Inorg. Chem., 2003, 42, 2049-2055.
50. Chauhan, M.; Arjmand, F. Chiral and achiral macrocyclic copper(II) complexes: synthesis, characterization, and comparativebinding studies with calf-thymus DNA. Chem. Biodiv., 2006, 3, 660-676.
51. Krotz, A.H.; Kuo, L.Y.; Shields, T.P.; Barton, J.K. DNA recognition by rhodium(III) polyamine intercalators: considerations of hydrogen bonding and van der Waals interactions. J. Am. Chem. Soc., 1993, 115, 3877.
52. Mandal, S.S.; Varshney, U.; Bhattacharya, S. Role of the Central Metal Ion and Ligand Charge in the DNA Binding and Modification by Metallosalen Complexes. Bioconjugate Chem., 1997, 8, 798-812.
53. Modukuru, N.K.; Snow, K.J.; Perrin, Jr B.S.; Thota, J.; Kumar, C.V. Contributions of a long side chain to the binding affinity of an anthracene derivative to DNA. J. Phys. Chem. B., 2005, 109, 11810-11818.
54. Midorikawa, K.; Kawanishi, S. Superoxide dismutases enhance H2O2-induced DNA damage and alter its site specificity. FEBS. Lett., 2001, 495, 187-190.
55. Christie, M.S.; Kenneth, L.R.; David, B.W. Assessing toxicity of fine and nanoparticles: Comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol. Sci., 2007, 97, 163-180.
56. Situ, H.; Bobek, L.A. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain1. Antimicrob. Agents Chemother., 2000, 44, 1485-1493.